ALECTOR
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in disco... very and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
ALECTOR
Industry:
Biotechnology Genetics Health Care Therapeutics
Founded:
2013-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.alector.com
Total Employee:
101+
Status:
Active
Contact:
(415) 231-5660
Total Funding:
269.5 M USD
Technology used in webpage:
Domain Not Resolving Amazon Pound Sterling Japanese Yen Amazon Route 53 DigiCert SSL Amazon SSL Amazon Oregon Region Amazon Ohio Region Akamai Hosted
Similar Organizations
Audentes Therapeutics
Audentes is a biotechnology company that employs gene therapy technology to develop treatments for people with rare muscle diseases.
Berkeley Lights
Berkeley Lights is a provider of research and development services using micro-droplet technology that change the biological processes.
Imara
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
Invitae
Invitae is a medical genetics company that bring comprehensive genetic information into mainstream medicine to improve healthcare.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Xenothera
Xenothera is a xenotherapy platform with embedded technology that renovates immunological treatments.
Current Advisors List
Board_member
2013-01-01
Board_member
2018-10-01
Board_member
2013-10-01
Board_member
2013-10-01
Board_member
2018-10-01
Board_member
2018-11-01
Current Employees Featured
Arnon Rosenthal Founder, President & Chief Executive Officer @ Alector
Founder, President & Chief Executive Officer
2013-05-01
Robert Paul Chief Medical Officer @ Alector
Chief Medical Officer
2016-10-01
Virginia DeJesus-Rueff VP of Portfolio and Program Management @ Alector
VP of Portfolio and Program Management
Marina Roell Principal Scientist @ Alector
Principal Scientist
2018-10-01
Charles Wolfus VP of Technology and Digital Health @ Alector
VP of Technology and Digital Health
2019-01-01
Herve Rhinn Head of Target Discovery and Genomics @ Alector
Head of Target Discovery and Genomics
Kristina Vlaovic Vice President of Regulatory Affairs & Pharmacovigilance @ Alector
Vice President of Regulatory Affairs & Pharmacovigilance
Calvin Yu VP Finance @ Alector
VP Finance
George Yam FACS, Associate Director @ Alector
FACS, Associate Director
2022-06-01
Errik Anderson Co-Founder @ Alector
Co-Founder
2013-02-01
Founder
Stock Details
Investors List
OrbiMed
OrbiMed investment in Series E - Alector
Mission Bay Capital
Mission Bay Capital investment in Series E - Alector
Euclidean Capital
Euclidean Capital investment in Series E - Alector
Google Ventures
Google Ventures investment in Series E - Alector
Polaris Partners
Polaris Partners investment in Series E - Alector
Section 32
Section 32 investment in Series E - Alector
Deerfield Capital Management
Deerfield Capital Management investment in Series E - Alector
Amgen Ventures
Amgen Ventures investment in Series E - Alector
Mission BioCapital
Mission BioCapital investment in Series E - Alector
Casdin Capital
Casdin Capital investment in Series E - Alector
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-02-07 | INmuneBIO | Alector investment in Post-IPO Equity - INmuneBIO | 8.17 M USD |
Official Site Inspections
http://www.alector.com Semrush global rank: 2.85 M Semrush visits lastest month: 5.83 K
- Host name: 23.185.0.3
- IP address: 23.185.0.3
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Alector"
Our Executive Leadership & Board of Directors - Alector
Virginia joined Alector in 2018, leading the Portfolio and Program Management function. Prior to Alector, Virginia held various roles of increasing responsibility at Genentech from 2007 through 2018, including in the global organization as a Disease Area Director and LifeCycle Leader.See details»
About Us - Alector
Alector is on a mission to develop therapies that improve healthy function to the brain. By unlocking the power of immunology, neuroscience, and human genetics, we’re trailblazing immuno-neurology—a visionary therapeutic approach to …See details»
Alector - Crunchbase Company Profile & Funding
Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology …See details»
Alector Corporate Overview
Alector is not aware of any other TREM2-activating candidates in a Phase 2 or a Phase 3 trial for AD, PGRN-elevating candidates in a Phase 3 trial for FTD, or PGRN-elevating candidates in a Phase 2 or Phase 3 trial for AD as of August 2024. 2. Cash, cash equivalents, and marketable …See details»
Investors | Alector
Nov 6, 2024 At Alector, we are on a mission to slow the progression of neurodegenerative diseases and one day prevent their occurrence. We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of …See details»
Alector, Inc. (ALEC) Company Profile & Facts - Yahoo Finance
Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to …See details»
Alector Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Alector has 5 employees at their 1 location and $97.06 m in annual revenue in FY 2023. See insights on Alector including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
ALECTOR, INC. CORPORATE GOVERNANCE AND NOMINATING …
ALECTOR, INC. CORPORATE GOVERNANCE AND NOMINATING COMMITTEE CHARTER As revised March 2024 The Corporate Governance and Nominating Committee (the “Committee”) of the Board of Directors (the “Board”) of Alector, Inc. (the “Corporation”) will be appointed by the …See details»
Alector - VentureRadar
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The company is developing a broad portfolio of innate immune system programs, designed to functionally …See details»
Alector Inc Company Profile - Alector Inc Overview - GlobalData
Alector also generates and validates antibody drugs that engage key disease-altering and genetically validated neuroimmune targets. The company develops drugs through collaborations with scientists and drug developers. It operates a manufacturing facility in Milpitas, California. …See details»
Our History Overview - Alector
Alector and Adimab announce strategic alliance to access antibody technologies. Co-founders Arnon Rosenthal, Ph.D., Tillman Gerngross and Errik Anderson launch Alector with announcement of Series A financing from Orbimed and Polaris Ventures. Alector moves to life …See details»
Alector Mission, Benefits, and Work Culture | Indeed.com
At Alector, our mission is to develop therapies that empower the immune system to cure neurodegeneration. Our team is solely focused on developing cures for some of the most challenging diseases facing our society. We are supported in this mission by experienced and …See details»
Mission, Vision & Core Values of Alector – CANVAS, SWOT, …
Dec 7, 2024 The Alector Mission, Vision & Core Values: Alector is a cutting-edge biotechnology company dedicated to revolutionizing the treatment of neurodegenerative diseases. Our mission is to develop innovative therapies that target the underlying causes of these devastating …See details»
Alector turns to layoffs as Alzheimer’s drug fails
Nov 26, 2024 In an emailed statement, a company spokesperson said the reductions were across the organization. As of Sept. 30, Alector had $457 million in cash, cash equivalents and investments, which the company estimates are enough resources to stay operational through …See details»
Alector Reports on Recent Progress and Outlines Strategic …
2 days ago Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology and neuroscience, the company is advancing a …See details»
Working at Alector - Great Place To Work®
89% of employees at Alector say it is a great place to work . ... Today, our Trust Model™ offers an unmatched opportunity to identify what’s happening within your organization. Great Place To Work’s survey and analysis gives employers the ability to measure and track employee …See details»
Alector Reports on Recent Progress and Outlines Strategic …
2 days ago SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the ...See details»
How Does Alector Work? – CBM - canvasbusinessmodel.com
Dec 7, 2024 Global Alliances: Alector forms alliances with international organizations and regulatory bodies to expand its global presence and access new markets for its therapies. These alliances help Alector navigate complex regulatory environments, establish strategic …See details»
Our Mission - Alector
At Alector, we are on a mission to slow the progression of neurodegenerative diseases and to one day prevent their occurrence. There are currently over 50 million people with neurodegeneration worldwide, with over 10 million new cases diagnosed each year. We envision a world where …See details»
Alector, Inc. Advances Neurodegeneration Pipeline with Key
1 day ago Alector, Inc., a late-stage clinical biotechnology company, is advancing its preclinical and research pipeline focused on genetically-validated therapies for neurodegenerative diseases. The ...See details»